On the stock market since 1980, it operates in the world of health and science. It has 64,317 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (1% a year). Red columns mark years that ended in a loss.
The gap is $5.3B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.99 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 0% a year on average. At this size, speeding back up is not easy.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, PHG sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PHG is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.